MA39719B1 - Pyrazoles substituted with trifluoromethyl as inhibitors of human plasma kallikrein - Google Patents
Pyrazoles substituted with trifluoromethyl as inhibitors of human plasma kallikreinInfo
- Publication number
- MA39719B1 MA39719B1 MA39719A MA39719A MA39719B1 MA 39719 B1 MA39719 B1 MA 39719B1 MA 39719 A MA39719 A MA 39719A MA 39719 A MA39719 A MA 39719A MA 39719 B1 MA39719 B1 MA 39719B1
- Authority
- MA
- Morocco
- Prior art keywords
- plasma kallikrein
- inhibitors
- trifluoromethyl
- human plasma
- compounds
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 101001091365 Homo sapiens Plasma kallikrein Proteins 0.000 title 1
- 150000003217 pyrazoles Chemical group 0.000 title 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 102000003827 Plasma Kallikrein Human genes 0.000 abstract 2
- 108090000113 Plasma Kallikrein Proteins 0.000 abstract 2
- 230000006806 disease prevention Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Cette invention concerne des composés de formule (i), et leurs sels de qualité pharmaceutique. Les composés sont des inhibiteurs de la kallicréine plasmatique l'invention concerne également des compositions pharmaceutiques comprenant au moins un composé de l'invention, et des procédés impliquant l'utilisation des composés et des compositions de l'invention dans le traitement et la prévention de maladies et de pathologies caractérisées par une activité indésirable de la kallicréine plasmatique.This invention relates to compounds of formula (i), and their pharmaceutical grade salts. The compounds are inhibitors of plasma kallikrein The invention also relates to pharmaceutical compositions comprising at least one compound of the invention, and to methods involving the use of the compounds and compositions of the invention in the treatment and prevention of diseases and pathologies characterized by undesirable activity of plasma kallikrein.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461949808P | 2014-03-07 | 2014-03-07 | |
| PCT/US2015/019535 WO2015134998A1 (en) | 2014-03-07 | 2015-03-09 | Human plasma kallikrein inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA39719B1 true MA39719B1 (en) | 2020-12-31 |
Family
ID=74126541
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA39719A MA39719B1 (en) | 2014-03-07 | 2015-03-09 | Pyrazoles substituted with trifluoromethyl as inhibitors of human plasma kallikrein |
Country Status (1)
| Country | Link |
|---|---|
| MA (1) | MA39719B1 (en) |
-
2015
- 2015-03-09 MA MA39719A patent/MA39719B1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA53399B1 (en) | Substituted pyrazoles as inhibitors of human plasma kallikrein | |
| EA201990665A1 (en) | HPK1 REGULATORS BASED ON PYRAZOLOPYRIDINE DERIVATIVES AND THEIR APPLICATION FOR TREATMENT OF CANCER | |
| MA41179A (en) | PARG INHIBITOR COMPOUNDS | |
| PH12018500041A1 (en) | Substituted aza compoounds as irak-4 inhibitors | |
| PH12018500040A1 (en) | Indazole and azaindazole compounds as irak-4 inhibitors | |
| MA40290A1 (en) | Immune-regulating agents | |
| MA43979B1 (en) | 1h-indazole-3-carboxamide derivatives and similar compounds as d-factor inhibitors for the treatment of diseases characterized by aberrant activity of the complementary system, such as p.E. Immunological disorders | |
| EA201792047A1 (en) | NEW CONNECTIONS | |
| MA40123A1 (en) | Pyrimidines used as factor xia inhibitors | |
| MA40111A1 (en) | Derivatives of tetrahydronaphthalene inhibiting mcl-1 protein | |
| MA39783A (en) | USEFUL QUINOXALINE DERIVATIVES AS FGFR KINASE MODULATORS | |
| MA39726A (en) | PHARMACEUTICAL COMPOSITIONS OF THERAPEUTICALLY ACTIVE COMPOUNDS | |
| MA47356B1 (en) | Isochromene derivatives useful as inhibitors of phosphoinositide 3-kinases | |
| JOP20180036A1 (en) | Salts for new fruortin inhibitors | |
| MA39725B1 (en) | Pharmaceutical compositions of therapeutically active compounds | |
| MA43052B1 (en) | Human Plasma Kallikrein Inhibitors | |
| MA34545B1 (en) | CO-CRYSTALS AND SALTS OF CCR3 INHIBITORS | |
| MA34968B1 (en) | ASYMMETRIC UREA AND MEDICAL USES THEREOF | |
| MA47736B1 (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | |
| GB2533454A (en) | Therapeutic compounds as inhibitors of the orexin-1 receptor | |
| MA40875A (en) | 2,4-DIAMINO-QUINOLEIN SUBSTITUTED AS NEW ANTI-CANCER AGENTS | |
| EA201692481A1 (en) | COMBINATION CONTAINING GLUCOCORTICOID AND EDO-S101 | |
| JOP20200100A1 (en) | Pyrazolo-pyrrolo-pyrimidine-diene derivatives are new as P2X3 inhibitors | |
| MX2020010552A (en) | BUMETANIDE DERIVATIVES FOR THE TREATMENT OF HYPERHIDROSIS. | |
| MX2019006863A (en) | Heparanase inhibitors and use thereof. |